C-Flox 500 (Ciprofloxacin)
ciprofloxacin 500 mg tablet, 14 · ORAL · PBS code 1209P
AUTHORITY_REQUIREDWhat it costs
AU$4 PBS-determined price per 14 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2002-02-01.
- • Repeats: 0.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Respiratory tract infection
The condition must be proven or suspected to be caused by Pseudomonas aeruginosa; AND
Patient must be severely immunocompromised.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Bacterial gastroenteritis
Patient must be severely immunocompromised.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Infection
The condition must be proven to be due to Pseudomonas aeruginosa resistant to all other oral antimicrobials; or
The condition must be proven to be due to other gram-negative bacteria resistant to all other oral antimicrobials.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Bone or joint infection
The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or
The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Epididymo-orchitis
The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or
The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Prostatitis
The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or
The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Perichondritis of the pinna
The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or
The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.
Sponsor: Alphapharm Pty Ltd ABN 93 002 359 739
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.